Janus kinase inhibitors for the treatment of COVID-19-Reference-Cited by-同舟云学术

Janus kinase inhibitors for the treatment of COVID-19

Published:2022-06-13 Issue:6 Volume:2022 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Kramer Andre¹,Prinz Carolin²,Fichtner Falk¹,Fischer Anna-Lena¹,Thieme Volker¹,Grundeis Felicitas¹,Spagl Manuel¹,Seeber Christian¹,Piechotta Vanessa³,Metzendorf Maria-Inti⁴,Golinski Martin²,Moerer Onnen²,Stephani Caspar²,Mikolajewska Agata⁵,Kluge Stefan⁶,Stegemann Miriam⁵,Laudi Sven¹,Skoetz Nicole⁷

Affiliation:

1. Department of Anaesthesiology and Intensive Care; University of Leipzig Medical Center; Leipzig Germany

2. Department of Anesthesiology; University Medical Center Göttingen, Georg August University; Göttingen Germany

3. Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

4. Institute of General Practice; Medical Faculty of the Heinrich-Heine-University Düsseldorf; Düsseldorf Germany

5. Department of Infectious Diseases and Respiratory Medicine; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin; Berlin Germany

6. Department of Intensive Care Medicine; Medical Center Hamburg Eppendorf (UKE); Hamburg Germany

7. Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany

Publisher

Wiley

Subject

Pharmacology (medical)

Reference174 articles.

1. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial;Cao;Journal of Allergy and Clinical Immunology,2020

2. Ely EW Ramanan AV Kartman CE de Bono S Liao R Piruzeli ML Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial Lancet Respiratory Medicine 10.1016/S2213-2600(22)00006-6

3. Ely EW Ramanan AV Kartman CE de Bono S Liao R Piruzwli ML Baricitinib plus standard of care for hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: results of a randomised, placebo-controlled trial medRxiv [Preprint] 10.1101/2021.10.11.21263897

4. Tofacitinib in patients hospitalized with Covid-19 pneumonia;Guimarães;New England Journal of Medicine,2021

5. Horby P Emberson JR Mafham M Thwaites G Haynes R Landray MR Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis medrxiv.org [preprint]. Available at: www.medrxiv.org/content/10.1101/2022.03.02.22271623v1 10.1101/2022.03.02.22271623

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Choosing immunomodulating therapies for the treatment of COVID-19: recommendations based on placebo-controlled trial evidence;Clinical Microbiology and Infection;2024-05

2. A Girl With Adenovirus Type 2 Induced Interstitial Pneumonitis Acutely Exacerbated With Primary Human Herpesvirus 7 Infection;Pediatric Infectious Disease Journal;2024-02-28

3. Tofacitinib in Patients Hospitalized With Moderate and Severe COVID-19: Not Just Another Kinase Inhibitor;Cureus;2024-01-22

4. Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study;BMC Rheumatology;2024-01-17

5. An umbrella review on treatments and therapeutic options for COVID-19;Russian Journal of Infection and Immunity;2023-11-30